Kategori: Forskningsreferencer

Antioxidanter forskningsreferencer

Admin

Januar 1999

1. Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson’s disease. Eur J Clin Nutr 46:879-84, 1992.
2. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 7915-22.
3. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci. USA 1995; 92: 5258-65.
4. Azen SP, Qian D, Mack W, et al. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation 94;10:2369-72, 1996.
5. Bhat KS. Nutritional status of thiamine, riboflavin and pyridoxine in cataract patients. Nutr Rep Int 363:685-92, 1987.
6. Boers GH. Hyperhomocysteinaemia: A newly recognized risk factor for vascular disease. Neth J Med 45:1:34-41, 1994.
7. Boniton-Kopp C, Coudray C, Berr C, et al. Combined effects of lipid peroxidation and antioxidant status on carotid atherosclerosis in a population aged 59-71 y: The Eva study. Am J Clin Nutr 65:121-7, 1997.
8. Brattström L. Vitamins as homocysteine-lowering agents: A mini review. Presentation at the American Institute of Nutrition Colloquium, April 13, 1995, Atlanta, Georgia; Brattström L. Vitamins as homocysteine-lowering agents. J Nutr 126:4 Suppl:1276S-1280S, 1996.
9. Calzada C, Bruckdorfer K, Rice-Evans C. The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis 128;1: 97-105, 1997.
10. Cerhan JR, Wallace RB, Folsom AR. Antioxidant intake and risk of Parkinson’s Disease in older women. Am J Epidemiol 139;11:S65, 1994.
11. De Lorgeril , Boissonnat P, Salen P, et al. The beneficial effect of dietary antioxidant supplementation on platelet aggregation and cyclosporine treatment in heart transplant recipients. Transplantation 58:193-4, 1994.
12. De Rijk MC et al. Dietary antioxidants and Parkinson disease: The Rotterdam study. Arch Neurology 54:762-5, 1997.
13. Ely J. Crary, Smyrna, Georgia, USA – quoted in Zarrow S. Keep your eyes young and sharp. Prevention March, 1985, pp. 74-80; Crary E. Antioxidant treatment of macular degeneration of the aging and macularedema in diabetic retinopathy. South Med J 80 no. 9, supple 3:38, 1987.
14. Fahn S. An open trial of high-dosage antioxidants in early Parkinson’s disease. Am J Clin Nutr 53:380S-1S, 1991.
15. Gartside PS, Glueck CJ. Relationship of dietary intake to hospital admission for coronary heart and vascular disease: The NHANES II National Probability Study. J Am Coll Nutr 12:6:5676-84, 1993.
16. Ghosh S, et al. Dietary intake and plasma levels of antioxidant vitamins in health and disease: A hospital-based case-control study. J Nutr Environ Med 5:235-42, 1995.
17. Grimes JD et al. Prevention of progression of Parkinson’s disease with antioxidative therapy. Prog Neuropsychopharmacol Biol Psychiatry 122-3:165-72, 1988.
18. Hankinson S, Stampfer M, Seddon J, et al. Nutrient intake and cataract extraction in women: A prospective study. BMJ 305: 335-9, 1992.
19. Heliovaara M, Knekt P, Aho K, et al. Serum antioxidants and risk of rheumatoid arthritis. Ann Rheum Dis 53: 51-3, 1994.
20. Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 273;23:1849-54, 1995.
21. Ince S. Vitamin Supplements may help delay onset of AIDS. Medical Tribune September 9, p.18, 1993.
22. Jacques PF, Chylack LT Jr, McGandy RB, Hartz SC. Antioxidant status in persons with and without senile cataract. Arch Ophthalmol 106:3:337-40, 1988.
23. Jacques PF, Chylack LT Jr. Epidemiologic evidence of a role for the antioxidant vitamins and carotenoids in cataract prevention. Am J Clin Nutr 53: 352S-5S, 1991.
24. Jacques PH et al. Vitamin intake and senile cataract. J Am Coll Nutr 6:5:435, 1987.
25. Jain VK, Chandra RK. Does nutritional deficiency predispose to Acquired Immune Deficiency Syndrome (AIDS)? Nutr Res 4:537-43, 1984.
26. Jariwalla RJ. Micro-nutrient imbalance in HIV infection and AIDS: Relevance to pathogenesis and therapy. J Nutr Environ Med 5:297-306, 1995.
27. Knekt P, Reunanen A, Jarvinen R, et al. Antioxidant vitamin intake and coronary mortality in an longitudinal population study. Am JEpidemiol 139:1180-9, 1994.
28. Knekt P, Heliovaara M, Rissanan A, et al. Serum antioxidant vitamins and risk of cataract. BMJ 305:1392-4, 1992.
29. Kritchevsky SB, Shimakawa T, Tell GS, et al. Dietary antioxidants and carotid artery wall thickness: The ARIC study. Circulation 92:8:2142-50, 1995.
30. Manson JE, Stampfer MJ, Willett WC, et al. A prospective study of antioxidant vitamins and incidence of coronary heart disease in women. Abstract. J Am Coll Nutr 11:5:633, 1992.
31. Mares-Perlman J, Klein R, Klein B, et al. Relationship between age-related maculopathy and intake of vitamin and mineral supplements. Invest Ophthalmol Vis Sci 34:1133, 1993.
32. McAlindon TE, Jacques P, Zhang Y, et al. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? Arthritis Rheum 39(4): 648-56,1996.
33. Mastroiacovo P et al. Antioxidant Vitamins and Immunodeficiency. Int J Vitam Nutr Res 66:141-5, 1996.
34. Mooradian AD et al. Selected Vitamin and Mineral in Diabetes. Diabetes Care 17; 464-79, 1994.
35. Newsome D et al. The trace element and antioxidant economy of the human macula: Can dietary supplementation influence the course of macular degeneration? J Am Coll Nutr 10:5:536, 1991.
36. Olson RJ. Supplemental dietary antioxidant vitamins and minerals in patients with macular degeneration. J Am Coll Nutr 10:5:550, 1991.
37. Olszewski AJ et al. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Atherosclerosis 75:1:1-6, 1989.
38. Pories WJ, Henzel JH, Hennessen JA. Proc U of Missouri First Annual Conference on Trace Substances in the Environment and Health 1968:114, 1967.
39. Rath M, Pauling L. A unified theory of human cardiovascular disease leading the way to the abolition of this disease as a cause for human mortality. J Orthomol Med 7:1:5-15, 1992.
40. Singh R, Niaz M, Bishnol J, et al. Diet, antioxidant vitamins, oxidative stress, and risk of coronary artery disease. Acta Cardiol 49:5:453-67, 1994.
41. Singh RB, Ghosh S, Niaz MA, et al. Dietary intake, plasma levels of antioxidant vitamins and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol 76:1233-8, 1995.
42. Singh RB, Niaz MA, Ghosh S, et al. Dietary intake and plasma levels of antioxidant vitamins in health and disease: A hospital-based case-control study. J Nutr Environ Med 5:235-42, 1995.
43. Singal PK, Kapur N, Dhillon KS et al. Role of free radicals in catecholamine induced cardiomyopathy. Can J Physiol Pharmacol 60:1390, 1982.
44. Snodderly DM. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr 62:suppl:1448S-61S, 1995.
45. Steinberg D.Antioxidants in the prevention of human Artherosclerosis. Circulation 85; 6; 2338-2344, 1992.
46. Tang A, Graham N, Kirby A, et al. Dietary micronutrient intake and the risk of progression to Acquired Immunodeficiency Syndrome (AIDS) in Human Immunodeficiency Virus Type 1 (HIV-1) infected homosexual men. Am J Epidemiol 138: 937-51, 1993.
47. Tang AM, Graham NM, Saah AJ. Effects of Micronutrient Intake on Survival in Human immunodeficiency virus type 1 Infection. Am J Epidemiol 143:1244-56, 1996.
48. Tavani A et al. Food and nutrient intake and risk of cataract. Ann Epidemiol 6:41-6, 1996.
49. Tolonen, Matti: Fria radikaler och antioxidantia i biologi och medicin. Vitaminers og spormineralers betydning for velfærdssygdomme. (Significance of vitamins and traceminerals in disease), Rigshospitalets Symposium, Pharma Nord Research, 1988 (in Danish/Swedish).
50. Vitale S, West S, Hallfrish H, et al. Plasma antioxidants and risk of cortical and nuclear cataract. Epidemiology 4:195-203, 1993.
Ward RJ et al. Reduced antioxidant status in patients with chronic alcoholic myopathy. Biochem Soc Trans 16:581, 1988.
51. Ward RJ, Peters TJ. The antioxidant status of patients with either alcohol-induced liver damage or myopathy. Alcohol Alcohol 27;4:359-65, 1992.
52. Weisberger JH. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 1995; 53: 226s.
53. West S, Vitale S, Hallfrisch J, et al. Are antioxidants or supplements protective for age-related macular degeneration? Arch Ophthalmol 112:222-7, 1994.
54. Woodside J et al. The effects of vitamin supplementation on cardiovascular risk. J Inherit Metabol Dis 19:Suppl 1:26/P51, 1996.

– Se også betacaroten, B6-vitamin, C-vitamin, E-vitamin, Q10, selen og zink.

Kilder:
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

A-vitamin og betacaroten forskningsreferencer

Admin

Januar 1999

1. Band P.R. et al. Treatment of Benign Breast Disease with Vitamin A. Prev Med 549-54, 1984.
2. Bendich A. Symposium conclusions: Biological actions of carotenoids. J Nutr 119: 112-5, 1989.
3. Bichler KH et al. Influence of vitamin A deficiency on the excretion of uromucoid and other substances in the urine of rats. Clin Nephrol 20:32-9, 1983.
4. Branowitz SA, Starrett B, Brookner AR. Carotene deficiency in HIV patients. AIDS 10; (1):115, 1996.
5. Burton GW, Ingold KU. Beta-carotene. An unusual type of lipid antioxidant. Scicnce 224: 569-573, 1984.
6. Cheraskin E, Ringsdorf WM, Medford FH. The ‘ideal’ daily vitamin A intake. Int J Vit Nutr Res 46: 11-13, 1976.
7. Chole Q. Vitamin A in the cochlea. Arch Otorhinolaryngol 124:379-82, 1978.
8. Comstock GW et al. Serum concentrations of alpha-tocopherol, beta-carotene, and retinol preceding the diagnosis of rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 56: 323-5, 1997.
9. Connett JE, Kuller KH, Kjelsberg MO et al. Relationship between carotenoids and cancer. Cancer 64: 126-134, 1989.
10. Coutsoudis A, Bobat R, Coovadia H. The effects of vitamin-A supplementation on the morbidity of children born to HIV-infected women. Am J Public Health 85; (8):1076-81, 1995.
11. Delmas-Beauvieux M-C, Peuchant E, Couchouron A, et al. The enzymatic antioxidant system in blood and glutathione status in human immunodeficiency virus (HIV)-infected patients: Effects of supplementation with selenium or carotene. Am J Clin Nutr 64: 101-7, 1996.
12. DiMascio P, Murphy ME, Sies H. Antioxidant defense systems the role of carotenoids, tocopherols and thiols. Am J Clin Nutr 53: 194S-200S, 1991.
13. Eldred GE. Vitamins A and E in RPE lipofuscin formation and implications for age-related macular degeneration. Prog Clin Biol Res 314: 113-29, 1989.
14. Ferreira R et al. Antioxidant action of vitamins A and E in patients submitted to coronary bypass surgery. Vasc Surg 25: 191-195, 1991.
15. Gaby SK, Singh VN. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 29-57, 1991.
16. Gershoff SN, McGandy RB. The effects of vitamin A-deficient diets containing lactose in producing bladder calculi and tumors in rats. Am J Clin Nutr 34: 483, 1981.
17. Goodman DS. Vitamin A and retinoids in heath and disease. N Eng J Med 310: 1023-1031, 1984.
18. Hayes KC. Retinal degeneration in monkeys induced by deficiencies of vitamin E or A. Invest Ophthalmol Vis Sci 13:7:499-510, 1974.
19. Honkanen V et al. Vitamins A and E, retinol binding protein and zinc in rheumatoid arthritis. Clin Exp Rheumatol 7: 465-9, 1989.
20. Honkanen VEA et al. Serum cholesterol and vitamins A and E in juvenile chronic arthritis. Clin Exp Rheumatol 8: 187-91, 1990.
21. Liao CH, Erdman JW, Johnston PV. Dietary vitamin A deficiency and the immune system in a murine model of systemic lupus erythematosus. Nutr Res 16: 279-92, 1996.
22. Lohle E. The influence of chronic vitamin A deficiency on human and animal ears. Arch Otorhinolaryngol 234:167-73, 1982.
23. Mckeown LA. Beta carotene lifts CD4 counts. Study reported in Medical Tribune Feb. 25, p. 1. 1993.
24. Mobarhan S, Bowen P, Andersen B et al. Effects of beta-carotene repletion on beta-carotene absorption, lipid peroxidation, and neutrophil superoxide formation in young men. Nutr Cancer 14: 195-206, 1990.
25. Newbold PCH. Beta-carotene in the treatment of discoid lupus erythematosus. Br J Dermatol 95: 100-1, 1976.
26. Olson JA. Vitamin A. In: Present knowledge in nutrition. 7th edn. Washington DC: Intemational Life Sciences Press. p 109-119, 1996.
27. Oson JA. Provitamin A function of carotenoids. Thc conversion of B-carotene to Vitamin A. J Nutr 119: 105-108, 1989.
28. Paganini-Hill A, Chao A, Ross RK et al. Vitamin A, beta carotene and the risk of cancer. A prospective study. J Natl Cancer Inst 79: 443-448, 1987.
29. Palgi A. Association between dietary changes and morality rates; Israel 1949 to 1977; a trend-free regression model. Am J Clin Nutr 34: 1569-1583, 1981.
30. Prince MR, Frisoli JK. Beta-carotene accumulation in serum and skin. Am J Clin Nutr 1993; 57: 175-181, 1993.
31. Pryor WA. The antioxidant nutrients and disease prevention what do we know and what do we need to find out? Am J Clin Nutr 53: 391S-393S, 1991.
32. Riemersma RA, Wood DA, MacIntyre CCH, et al. Risk of angina pectoris and plasma concentrations of vitamins A, C and E and carotene. Lancet 337:1-5, 1991.
33. Romeo G. The therapeutic effect of vitamins A and E in neurosensory hearing loss. Acta Vitaminol Enzymol 7 Suppl:85-92, 1985.
34. Sahyoun NR et al. Carotenoids, vitamins C and E, and mortality in an elderly population. Am J Epidemiol 144:5:501-11, 1996.
35. Sappey C et al. Vitamin, Trace element and Peroxide status in HIV seropositive patients: Asymptomatic patients present a severe Carotene Deficiency. Clin Clim Acta 230:35-42, 1994.
36. Semba R, Graham N, Caiaffa W, et al. Increased Mortality associated with Vitamin A Deficiency during Human Immunodeficiency Virus type 1 infection. Arch Intern Med 153:2149-54, 1993.
37. Semba RD, Park S, Royal W, Griffin DE. Vitamin A deficiency and T-cell subpopulation in HIV-infected adults. Nutr Res 16:915-23, 1996.
38. Sommer A., West, KP. The duration of the effect of vitamin A supplementation. Am J Public Health 1997; 87: 467, 1997.
39. Salonen JT. Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case-control analysis of prospective data. Br Mcd J 1985, 290: 417-420, 1985.
40. Schauss AG. Beta-carotene and the incidence of lung cancer in Finnish male smokers. A critique. Q Rev Natural Med 191-195, 1994.
41. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 272:1413-20, 1994.
42. Stahelin HB, Gey KB, Eichholzer M et al. Beta-carotene and cancer prevention. The Basel Study. Am J Clin Nutr 53: 265S-269S, 1991.
43. Street DA et al. Serum antioxidants and myocardial infarction: Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction? Circulation 90;3:1154-61, 1994.
44. Tang AM et al. Association between Serum Vitamin A and E levels and HIV-1 disease progression. AIDS 11:613-20, 1997.
45. Underwood BA. Was the ‘anti-infective’ vitamin misnamed? Nutr Rev 52: 140-143, 1994.
46. Vitale S et al. Plasma vitamin C, E and beta carotene levels and risk of cataract. Invest Ophthalmol Vis Sci 32:723, 1991.
47. Weisburger J. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 53: S226-237, 1991.
48. Weisberger JH. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 1995; 53: 226s.
49. Werler MA, Lammer EJ, Mitchell AA. Teratogenicity of high vitamin A intake. Letter. N Eng J Med 334: 1195, 1995.
50. White WS, Kim Cl, Kalkwarf HJ et al. Ultraviolet light-induced reduction in plasma carotenoid levels. Am J Clin Nutr 47: 879-883, 1988.
51. Willette W. Nutritional epidemiology. New York: Oxford University Press. p 292-310, 1990.
52. Ziegler RG. Vegetables, fruits and carotenoids and the risk of cancer. Am J Clin Nutr 53: 251S-259S, 1991.

Kilder
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

B1-vitamin, Thiamin forskningsreferencer

Admin

Januar 1999

1. Allison JR. The relation of hydrochloric acid and vitamin B complex deficiency in certain skin diseases. South Med J 38: 235-241, 1945.
2. Bendich A, Cohen M. Nutrition and Immunology. New York: Alan R. Liss. p 101-123, 1988.
3. Butterworth RF et al. Thiamin deficiency in AIDS. Lancet 338:1086, 1991.
4. Cheraskin E, Ringsdorf WM Jr, Setyaadmadja AT et al. Thiamin consumption and cardiovascular complaints. J Am Geriatrics Soc 15: 1074-1079, 1967.
5. Cheraskin E, Ringsdorf WM Jr, Setyaadmadja AT et al. Carbohydrate consumption and cardiovascular complaints. Angiology 18: 224-230, 1967.
6. Cheraskin E, Ringsdorf WM Jr, Medford FH et al. The ‘ideal’ daily vitamin B, intake. J Oral Med 33: 77-79, 1978.
7. Cheraskin E, Ringsdorf WM Jr. How much refined carbohydrate should we eat? Am Lab 6: 31-35, 1974.
8. Cummings F, Briggs M, Briggs, M. Vitamins in human biology and medicine. Boca Raton, FL: CRC Press. 1981.
9. Iber FL, Blass JP, Brin M et al. Thiamin in the elderly-relation to alcoholism and to neurological degenerative disease. Am J Clin Nutr 6: 1067-1082, 1982.
10. Lonsdale DA. Nutritionist’s guide to the clinical use of vitamin B1. Tacoma, WA: Life Sciences Press. p 1-209, 1987.
11. Lonsdale D. Red cell transketolase studies in a private practice specializing in nutritional correction. J Am Coll Nutr 7: 61-68, 1988.
12. Rindi, G. Thiamin. In: Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 160-166, 1996.
13. Ropert R. Utilisation de la Vitamine B1 fortes doses dans le traitement de divers syndromes douloureux facio-céphaliques. Sem Hôp 4:508-9, 1958 (in French).
14. Shils ME, Young VR. Modern nutrition in health and disease. 7th edn. Philadelphia: Lea and Febiger. p 358, 1988.

Kilder
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

B2-vitamin, Riboflavin forskningsreferencer

Admin

Januar 1999

1. Belko AZ, Obarzanek E, Kalkwarf HJ et al. Effects of exercise on riboflavin requirements of young women. Am J Clin Nutr 37: 509-517, 1983.
2. Belko AZ, Obazanek E, Roach R et al. Effects of aerobic exercise and weight loss on riboflavin requirements of moderately obese, marginally deficient young women. Am J Clin Nutr 40: 553-561, 1984.
3. Belko AZ, Meredith MP, Kalkwarf HJ et al. Effects of exercise on riboflavin requirements. Biological validation in weight reducing women. Am J Clin Nutr 41: 270-277, 1985.
4. Bendich A, Cohen M. Nutrition and Immunology. New York: Alan R. Liss. p. 114, 1988.
5. Beutler E. Glutathione reductase. Stimulation in normal subjects by riboflavin supplementation. Science 165: 614-615, 1969.
6. Goodwin JS, Garry PJ. Relationship between megadose vitamin supplementation and immunological function in a healthy elderly population. Clin Exp Immunol 51: 647-653, 1983.
7. Joint, FAO/WHO Expert Group. Riboflavin. WHO Technical Report Series No. 362. p. 86, 1967.
8. Prchal JT, Conrad ME, Skalka HW. Association of presenile cataracts with heterozygosity for glactosaemic states and riboflavin deficiency. Lancet i: 12-143, 1978.
9. Rivlin RS. Riboflavin. In: Ziegler EE, Filer LJ Jr, eds. Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 167-173, 1996.
10. Salim-Hanna M, Edwards AM, Silva E. A photo-induced adduct between a vitamin and an essential amino acid: binding of riboflavin to tryptophan. Int J Vit Nutr Res 57: 155-159, 1987.
11. Schoenen J, Jacquay J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 50: 466-470, 1998.
12. Schoenen J, Lenaerts M, Bastings E. High-dosc riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 14: 328-329, 1994.
13. Skalka HW, Prchal JT. Cataracts and riboflavin deficiency. Am J Clin Nutr 34: 861-863, 1981.
14. Webster RP, Gawde MD, Bhattacharya RK. Modulation of carcinogen-induced DNA damage and repair enzyme activity by dietary riboflavin. Cancer Lett 98: 129-135, 1996.
15. Weisburger J. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and cartenoids. Am J Clin Nutr 53: S226-227, 1991.

Kilder
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

B3-vitamin, Niacin, forskningsreferencer

Admin

Januar 1999

1. Alhadeff L, Gualtieri GT, Lipton M. Toxic effects of water-soluble vitamins. Nutr Rev 42: 33-40, 1984.
2. Bendich A, Cohen M. Nutrition and immunology. New York: Alan R. Liss. p 114-115, 1988.
3. Carlson LA, Hamsten A, and Asplund A. Pronounced Lowering of Serum Levels of Lipoprotein Lp(a) in Hyperlipidaemic Subjects Treated with Nicotinic Acid, J Intern Med 226, 271-6, 1989.
4. Cheraskin E, Ringsdorf WM Jr, Medford FH. The ‘ideal’ daily niacin intake. Int J Vit Nutr Res 46: 58-60, 1976.
5. Cleary JP. Vitamin B3 in the Treatment of Diabetes Mellitus: Case Reports and Review of the Literature. J Nutr Med 1: 217-25, 1990.
6. DiPalma JR and Thayer WS, Use of Niacin as a Drug, Ann Rev Nutr 11; 169-87, 1991.
7. Einstein N, Baker A, Galper J et al. Jaundice due to nicotinic acid therapy. Am J Digest Dis 20: 282-286, 1975.
8. El-Enein AMA et al., The Role of Nicotinic Acid and Inositol Hexaniacinate as Anticholesterolemic and Antilipemic Agents, Nutr Rep Intl 28, 899-911, 1983.
9. Figge HL, Figge J, Souney PF et al. Nicotinic acid. A review of its clinical use in the treatment of lipid disorders. Pharmacotherapy 8: 287-294, 1988.
10. Gaby SK. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 189-192, 1991.
11. Goldsmith GA, Miller ON, Unglaub WG. Efficiency of tryptophan as a niacin precursor in man. J Nutr 73: 172-176, 1961.
12. Grundy SM. Drug therapy in dyslipidemia. Scand J Clin Lab Invest 50: 63-72, 1990.
13. Illingworth DR et al., Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia, Arch Intern Med 154, 1586-95, 1994.
14. Jacob, RA, Swendseid, ME. Niacin. In: Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 184-190, 1996.
15. Jonas WB et al. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res 45: 330-4, 1996.
16. Lefavi R. Lipid-lowering effects of a dietary nicotinic acid-chromium III complex in male athletes. FASEB J 5;6:A1645, 1991.
17. Lefavi R et al. Lipid-lowering effect of a dietary chromium III-nicotinic acid complex in male athletes. Nutr Res 13:239-49, 1993.
18. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high density lipoprotein cholesterol ratio. Arch Intern Med 148: 2493-5, 1988.
19. Mandrup Paulsen T. Nicitinamide in the Prevention of Insulin Dependent Diabetes Mellitus. Diabetes Metabol Rev 9: 295-309, 1993.
20. McKenney JM et al., A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients, JAMA 271, 672-7, 1994.
21. O’Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (I lexopal) in intermittent claudication of a controlled trial. Br J Clin Practice 42: 377-383, 1988.
22. Patterson JI, Brown RR, Lindswiler H et al. Exertion of tryptophan-niacin metabolites by young men. Effects of tryptophan, leucine, and vitamin B6 intakes. Am J Clin Nutr 33: 2157-2167, 1980.
23. Pocoit F, Reimers JI and Andersen HU. Nicotinamide: Biological Actions and Therapeutic Potential in Diabetes Prevention. Diabetologia 36: 574-76, 1993.
24. Pozzilli P et al. The Potential Role of Nicotinamide in the Secondary Prevention of IDDM. Diabetes Metabol Rev 9: 219-30, 1993.
25. Salem and Abdel M. The Role of Nicotinic Acid and Inositol Hexaniacinate as Anticholesterolemic and Antilipemic Agents. Nutr Rep Intl 28: 899-911, 1983.
26. Urberg M and Zemel MB. Evidence for Synergism Between Chromium and Nicotinic Acid in the Control of Glucose Tolerance in Elderly Humans. Metabolism 36: 896-99, 1987.
27. Urberg M et al. Hypocholesterolemic effect of nicotinic acid and chromium supplementation. J Fam Pract 27;6:603-6, 1988.
28. Vega GL and Crundy SM. Lipoprotein Responses to Treatment with Lovastatin, Gemfibrozil, and Nicotinic Acid in Normolipidemic Patients with Hypoalphalipoproteinemia, Arch Intern Med 154: 73-82, 1994.
29. Welsh AL and Ede M, Inositol Hexanicotinate for Improved Nicotinic Acid Therapy, Int Record Med 174: 9-15, 1961.

Kilder
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

B5-vitamin, Pantothensyre forskningsreferencer

Admin

Januar 1999

1. Barton-Wright EC, Elliott WA. The Pantothenic Acid Metabolism of Rheumatoid Arthritis. Lancet ii: 862-3, 1963.
2. Fry PC et al. Metabolic response to a pantothenic acid deficient diet in humans. J Nutr Sci Vitaminol 22: 339-46, 1976.
3. Welsh AL. Lupus erythematosus: Treatment by combined use of massive amounts of pantothenic acid and vitamin E. Arch Dermatol Syphilol 70: 181-98, 1954.


Kilder
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

B6-vitamin, Pyridoxin forskningsreferencer

Admin

Januar 1999

1. Annand JC. Pyridoxine and magnesium in the treatment of shock. Lancet ii: 340-1, 1957.
2. Antopol W, Schotland CE. The use of vitamin B6 in pseudohypertrophic muscular dystrophy. JAMA, March 23, pp. 1058-9, 1940.
3. Barr W, Pyridoxine Supplements in the Premenstrual Syndrome, Practitioner 228: 425-7, 1984.
4. Bassler KH. Megavitamin therapy with pyridoxine. Int J Vit Nutr Res 58: 105-118, 1988.
5. Berman MK, et al. Vitamin B6 in Premenstrual Syndrom, J Am Diet Assoc 90 : 859-61, 1990.
6. Brattström L et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 81:1:51-60, 1990.
7. Brattström L, Stavenow L, Galvard H, et al. Pyridoxine reduces cholesterol and low-density-lipoprotein and increases antithrombin III activity in 80- year-old men with low plasma pyridoxal 5-phosphate. Scand J Clin Lab Invest 50:8:873-7, 1990.
8. Bum MK et al. Association of Vitamin B6 Status with Parameters of Immune Function in Early HIV-1 Infection. J AIDS 4:122-32, 1991.
9. Caby SK. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 163- 74, 1991.
10. Cohen M, Bendich A. Safety of pyridoxine – a review of human and animal studies. Toxicol Letters 34: 129-139, 1986.
11. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol 155:61847-51, 1996.
12. Dalery K et al. Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate and folate. Am J Cardiol 75:1107-11, 1995.
13. Driskell JA, Wesley RL, Hess IE. Effectiveness of pyridoxine hydrochloride treatment on carpal tunnel syndrome patients. Nutr Rep Int 1986; 34: 103-1040, 1986.
14. Ellis JM. Vitamin B6 deficiency and rheumatism. Anabolism Winter 1985.
15. Folkers K, Morita M, McRee Jr. J. The activities of coenzyme Q10 and vitamin B6 for immune response. Biochem Biophys Res Commun 193:88-92, 1993.
16. Gaby AR. The safe use of vitamin B6 J Nutr Med 1: 153-157, 1990.
17. Gershoff SN, Prien EL. Excretion of urinary metabolites in calcium oxalate urolithiasis: Effect of tryptophan and vitamin B6 administration. Am J Clin Nutr 8:812, 1960.
18. Gershoff S, Prien EL. Effect of daily MgO and vitamin B6 administration to patients with recurring calcium oxalate kidney stones. Am J Clin Nutr 20:393-399, 1967.
19. Gibbs DA, Watts RWE. The action of pyridoxine in primary hyperoxaluria. Clin.Sci 38:277-86, 1970.
20. Gvozdova LG, Paramonova EG, Goriachenkova EV et al. The content of pyridoxal coenzymes in the blood plasma of patients with coronary atherosclerosis on a background of therapeutic diet and after supplemental intake of vitamin B6. Vop Pitan 25: 40-44, 1966.
21. Hallert C, Astrom J, Walan A. Reversal of psychopathology in adult coeliac disease with the aid of pyridoxine (vitamin B6). Scand J Gastroenterol 18; (2):299-304, 1983.
22. Harrison AR et al. Hyperoxaluria and recurrent stone formation apparently cured by short course of pyridoxine. Br Med J 282: 2097-8, 1981.
23. Jaeger P. et al. Idiopathic hyperoxaluria cured by a short course of pyridoxine B6: Further evidence for B6-deficiency. Abstract. Clin Res 34, 2:546A, 1962.
24. Jones CL et al. Pyridoxine Deficiency: A New Factor in Diabetic Neuropathy. J Am Pod Assoc 68: 646-53, 1978.
25. Kasidas GP et al. Mild but clinically significant metabolic hyperoxaluria and its response to pyridoxine, in H von G Gasser, Wahlensieck W, Eds. Pathogenese und Klinik Harnstein XI. Darmstadt, Steinkopff Verlag, 394-9, 1985.
26. Kok FJ et al. Low vitamin B6 status in patients with acute myocardial infarction. Am J Cardiol 63:513-16, 1989.
27. Kuzuya F. Arteriosclerosis in pyridoxine deficient-monkeys. Primates 2:99, 1959.
28. Kuzuya F F. Experiment on arteriosclerosis and arteriolosclerosis induced in pyridoxine-deficient monkeys and their recovery. Primates 3:77, 1962.
29. Kuzuya F. Reversibility of arteriosclerosis in pyridoxine-deficient monkeys, in G Schettler, Y Goto, Y Hata, G Klose, Eds. Atherosclerosis IV. Berlin, Springer-Verlag, 275-8, 1977.
30. Kuzuya F. Vitamin B6 and arteriosclerosis. Nagoya J Med Sci 55:1-4:1-9, 1993.
31. Lam SC et al. Investigation of possible mechanisms of pyridoxal-5-phosphate inhibition of platelet reactions. Thrombosis Res 20:633-45, 1980.
32. Leklem, JE. Vitamin B-6. In: Present knowledge in nutrition.7th edn. Washington DC: International Life Sciences Press. p 174-83, 1996.
33. Levene CI, Murray JC. The aetiological role of maternal B6 deficiency in the development of atherosclerosis. Lancet i:628, 1977.
34. Lewy A, Fox N. Clinical notes; New instruments and technics: Pyridoxine (B6) used in the treatment of vertigo. Arch Otolaryngol pp.681-3, Nov. 1947.
35. Lyon E, Borden T, Ellis J, Vermeulen C. Calcium oxalate lithiasis produced by pyridoxine deficiency and inhibition with high magnesium diets. Invest Urol 4: 133-142, 1966.
36. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111-128, 1969.
37. Milliner D, Eickholt J, Berstrahl E, et al. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 331; 23:1553-8, 1994.
38. Mitwalli A et al. Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones. Int Urol Nephrol 20; 4:353-9, 1988.
39. Murthy MS, Farooqui S, Talwar HS, et al. Effect of pyridoxine supplementation on recurrent stone formers. Int J Clin Pharmacol Ther Toxicol 20; 9: 434-7, 1982.
40. Mushett CW, Emerson G. Arteriosclerosis in pyridoxine-deficient monkeys and dogs. Fed Proc 4:526-7, 1956.
41. Parry GJ, Bredesen DE. Sensory neuropathy with low dose pyridoxine. Neurology 1985; 35: 1466- 1468.
42. Prien EL, Gershoff S. Magnesium oxide-pyridoxine therapy for recurring calcium oxalate urinary calculi. J Urol 112:509-512, 1974.
43. Rattan VF, Sidhu H, Vaidyanathan S, et al. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers. Urol Res 22; 3:161-5, 1994.
44. Reinken L, Zieglauer H. Vitamin B6 absorption in children with acute celiac disease and in control subjects. J Nutr 108:1562, 1978.
45. Revusova V et al. The significance of oxaluria reduction by pyridoxine in prevention of calcium oxalate nephrolithiasis. Cas Lek Ces 121; 6:163-6, 1982.
46. Rinehart JF, Greenberg LD. Arteriosclerotic lesions in pyridoxine deficient monkeys. Am J Pathol 25:481-96, 1949.
47. Rinehart JF, Greenberg LD. Pathogenesis of experimental arteriosclerosis in pyridoxine deficiency with notes on similarities to human arteriosclerosis. Arch Pathol 51:12-29, 1951.
48. Rinehart JF, Greenberg LD. Vitamin B6 deficiency in the Rhesus monkey. Am J Clin Nutr 4:318-325, 1956.
49. Rhinehart JF, Greenberg LD. Vitamin B6 deficiency in the rhesus monkey, with particular reference to the occurrence of atherosclerosis, dental caries and hepatic cirrhosis. Am J Clin Nutr 4:318, 1956.
50. Roubenoff R et al. Abnormal vitamin B6 status in rheumatoid cachexia. Arthritis Rheum 1: 105-9, 1995.
51. Serofontein WJ, Ubbink JB, De Villiers LS, et al. Plasma pyridoxal-5-phosphate level as risk index for coronary artery disease. Atherosclerosis 55:3:357-61, 1985.
52. Serofontein WJ, Ubbink JB, De Villers LS, Becker PJ. Depressed plasma pyridoxal-5′-phosphate levels in tobacco-smoking men. Atherosclerosis. 59: 341-346; 1986.
53. Shor-Posner G, Feaster D, Blaney N, et al. Impact of Vitamin B6 Status on Psychological Distress in a longitudinal Study of HIV-1 infection. Int J Psychol Med 24; (3):209-22, 1994.
54. Shultz TD, Santamaria AG, Gridley DS et al. Effect of pyridoxine and pyridoxal on the in vitro growth of human malignant melanoma. Nutr Res 8: 201-207, 1988.
55. Solomon LR et al. Erythrocyte O2 Transport and Metabolism and Effects of Vitamin B6 Therapy in Type II Diabetes mellitus. Diabetes 38: 881-86, 1989.
56. Stone S. Pyridoxine and thiamine therapy in disorders of the nervous system. Dis Nerv Sys 11;5:131-8, 1950.
57. Subbarao K et al. Pyridoxal 5’-phosphate – a new physiological inhibitor of blood coagulation and platelet function. Biochem Pharmacol 28:531-4, 1979.
58. Swift ME, Shultz TD. Relationship of vitamins B6 and Bl2 to homocysteine levels: Risk for coronary heart disease. Nutr Rep Int 34: 1-14, 1986.
59. Talbott MC, Miller LT, Kerkvliet NI. Pyridoxine supplementation effect on Lymphocyte responses in elderly persons. Am J Clin Nutr 46: 659-664, 1987.
60. Thind SK et al. Role of vitamin B6 in oxalate metabolism in urolithiasis. Abstract. Am J Clin Nutr 32; 6:20, 1979.
61. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57:47-53, 1993.
62. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamin B6, B12, and folate. Am J Epidemiol 143:9:845-59, 1996.
63. Verrmaak WJ, Barnard HC, Potgieter GM et al. Plasma pyridoxal 5′-phosphate levels in myocardial infarction. S Afr Med J 70: 195-196, 1986.
64. Vermaak WJH et al. Vitamin B6 and coronary heart disease. Epidemiological observations and case studies. Atherosclerosis 63:235, 1987.
65. Vijayammal PL, Kurup PA. Pyridoxine and atherosclerosis: Role of pyridoxine in the metabolism of lipids and glycosaminoglycans in rats fed normal and high fat, high cholesterol diets containing 16% casein. Austral J Biol Sci 31:1:7-20, 1978.
66. Weisburger J. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidant, and carotenoids. Am J Clin Nutr 53: S226-S237, 1991.

Kilder
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Folinsyre, Folsyre, Folat, forskningsreferencer

Admin

Januar 1999

1. Alpert JE, Fava, M. Nutrition and depression. The role of folate. Nutr Rev 55: 145-149, 1997.
2. Bailey LB, Wagner PA, Davis CG, Dinning JS. Food frequency related to folacin status in adolescents. J Am Diet Assoc 84: 801-804, 1984.
3. Baker H, Jaslow SP, Frank O. Severe impairment of dietary folate utilization in the elderly. J Am Geriatr Soc 26: 218-221, 1978.
4. Bates CJ, Fleming M, Paul AA et al. Folate status and its relation to vitamin C in healthy elderly men and women. Age Aging 9: 241-248, 1980.
5. Bendich A, Cohen M. Nutrition and immunology. New York: Alan R. Liss. p 101-123, 1988.
6. Botez MI, Botez T, Léveillé J, et al. Neuropsychological correlates of folic acid deficiency: Facts and hypotheses, in MI Botez, EH Reynolds, Eds. Folic Acid in Neurology, Psychiatry, and Internal Medicine. New York, Raven Press, 435-461, 1979.
7. Brattstrom LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism 34: 1073-1077, 1987.
8. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid – an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 48: 3; 215-221, 1988.
9. Brattström L et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 81:1:51-60, 1990.
10. Briggs RM. Vitamin supplementation as a possible factor in the incidence of cleft lip/palate deformities in humans. Clin Plast Surg 1976; 3: 647-652, 1976.
11. Butterworth CE, Tamura T. Folic acid safety and toxicity. A brief review. Am J Clin Nutr 50: 353-358, 1989.
12. Center for Disease Control. Knowledge about folic acid and use of multivitamins containing folic acid among reproductive-aged women. Morbidity Mortality Weekly Report 45: 793-795, 1996.
13. Center for Disease Control. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. Morbidity Mortality Weekly Report 41: RR-14, 1996.
14. Clark AJ, Mossholder S, Gates R. Folacin status in adolescent females. Am J Clin Nutr 1987; 46: 302-306.
15. Dalery K et al. Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate and folate. Am J Cardiol 75:1107-11, 1995.
16. Deller DJ et al. Folic acid deficiency in rheumatoid arthritis. Relation of levels of serum folic acid activities to treatment with phenylbutazone. Br Med J i: 765-7, 1966.
17. Flynn MA, Irvin W, Krause G. The effect of folate and cobalamin on osteoarthritic hands. J Am Coll Nutr 13; 4: 351-6, 1994.
18. Gaby SK, Bendich A. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 175-188, 1991.
19. Gough KR et al. Folic acid deficiency in rheumatoid arthritis. Br Med J i: 212-17, 1964.
20. Halsted CH, Reisenauer AM, Romero JJ, et al. Jejunal perfusion of simple and conjugated folates in celiac sprue. J Clin Invest 59: 933-40, 1977.
21. Hjelt K, Krasilnikoff PA. The impact of gluten on haematolgical status, dietary intakes of haemopoietic nutrients and vitamin B12 and folic acid absorption in children with coeliac disease. Acta Paediatr Scand 79; (10):911-19, 1990.
22. Huber AM, Wallins LL, DeRusso P. Folate nutriture in pregnancy. J Am Diet Assoc 88: 791-814, 1988.
23. Jacques P, Bostom A, Williams R, et al. Relation between folate status, a common mutation in methylene tetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93; 1: 7-9, 1996.
24. Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 36: 458-462, 1987.
25. Laurence KM, James N, Miller MH et al. Double-blind randomized controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J 282: 1509-1511, 1981.
26. Milunsky A, Jick H, Jick SS, Bruell CL, MacLaughlin DS, Rothman KJ, Willette W. Multivitamin/folic acid supplementation in early pregnancy reduces the pr-reviewence of neural tube defects. J Am Med Assoc 262: 2847-2852, 1989.
27. Modesto C, Castro L. Folinic acid supplementation in patients with juvenile rheumatoid arthritis treated with methotrexate. J Rheumatol 23; (2): 403-4, 1996.
28. Morgan SI, Alarcon GS, Krumdieck CL. Folic acid supplementation during methotrexate therapy: It makes sense. Editorial. J Rheumatol 20; (6): 929-30, 1993.
29. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 121: 833-41, 1994.
30. Murray, MT. reviewuating the many benefits of folic acid. Am J Natural Med 3: 8-11, 1996.
31. Omer A, Mowat AG. Nature of anaemia in rheumatoid arthritis. IX. Folate metabolism in patients with rheumatoid arthritis. Ann Rheum Dis 27: 414-24, 1968.
32. Preuss HG. CRC Handbook series in nutrition and food. Section F: Nutntional disorders, vol. 1. Boca Raton, FL: CRC Press. p 61-62, 1978.
33. Selhub, J, Rosenberg, IH. Folic acid. In: Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 206-219, 1996.
34. Smithells RW, Nevin NC, Seller MJ et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1: 1027-1031, 1983.
35. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57:47-53, 1993.
36. Ventura A, bouquet F, Sartorelli C, et al. Coeliac disease, folic acid deficiency and epilepsy with cerebral calcifications. Acta Paeditr Scand 80; (5):559-62, 1991.
37. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamin B6, B12, and folate. Am J Epidemiol 143:9:845-59, 1996.
38. Weisburger JH. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 53: S226-S237, 1991.

Kilder
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

B12-vitamin, Cobalamin forskningsreferencer

Admin

Januar 1999

1. Allen, LH, Casterline J. Vitamin Bl2 deficiency in elderly individuals. diagnosis and requirements. Am J Clin Nutr 60: 12-14, 1994.
2. Baker H et al. Plasma vitamin B12 titres as indicators of disease severity and mortality of patients with alcoholic hepatitis. Alcohol Alcoholism 22; (1):15, 1987.
3. Brinton LA, Gridley G, Hrubec A et al. Cancer risk following pernicious anemia. Br J Cancer 59: 810-813, 1989.
4. Campbell RE, Pruitt FW. Vitamin B12 in the treatment of viral hepatitis. Am J Med Sci 224:252, 1952.
5. Campbell RE, Pruitt FW. The effect of vitamin B12 and folic acid in the treatment of viral hepatitis. Am J Med Sci 229:8-15, 1955.
6. Carethers M. Diagnosing vitamin Bl2 deficiency, a common geriatric disorder. Geriatrics 43: 89-112, 1988.
7. Chu RC, Hall CA. The total serum homocysteine as an indicator of vitamin Bl2 and folate status. Am J Clin Pathol 90: 446-449, 1988.
8. Dalery K et al. Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate and folate. Am J Cardiol 75:1107-11, 1995.
9. Davidson S. The Use of Vitamin B12 in the Treatment of Diabetic Neuropathy. J Flor Med Assoc 15: 717-20, 1954.
10. Doscherholmen A, Swaim WR. Impaired assimilation of egg 57 Co vitamin Bl2 in patients with hypochlorhydria and achlorhydria and after gastric resection. Gastroenterol 1973; 64: 913-919.
11. Ellis FR, Nasser S. A pilot study of vitamin B12 in the treatment of Tiredness. Br J Nutr 30: 277-83, 1973.
12. Gaby SK, Bendich A. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 193-197, 1991.
13. Gaby AR. The story of vitamin B12: Is vitamin B12 a panacea or placebo? Nutrition & Healing 2; 7, July, 1995.
14. Goodman KI, Salt WB 2nd. Vitamin B12 deficiency. Important new concepts in recognition. Postgrad Med 88; 3: 147-50, 153-8, 1990.
15. Gupta AK, Mital H.S. Cyanocobalamin (vitamin B12) in the management of Herpes Zoster. Indian Pract 20; (7):457-9, 1967.
16. Harriman GR et al. Vitamin B12 malabsorption in patients with acquired immunodeficiency syndrome. Arch Intern Med 149; (9):2039-41, 1989.
17. Heyblon R. Vitamin B12 in herpes zoster. Abstract. JAMA 146:1338, 1951.
18. Herbert, V. Vitamin B-l2. In: Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. 1996: p 191-205.
19. Heimburger DC, Alexander CB, Birch R, Bailey WC, Krumdieck CL. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin Bl2. J Am Mcd Assoc 259: 1525-1530, 1988.
20. Herbert V. B12 deficiency and AIDS. Letter. JAMA 260; (19):2837, 1988.
21. Herzlich BC et al. Synergy of inhibition of DNA synthesis in human bone marrow by azidothymidine plus deficiency of folate and/or vitamin B12? Am J Hematology 33:177-83, 1990.
22. Hjelt K, Krasilnikoff PA. The impact of gluten on haematolgical status, dietary intakes of haemopoietic nutrients and vitamin B12 and folic acid absorption in children with coeliac disease. Acta Paediatr Scand 79; (10):911-19, 1990.
23. Inada M, Toyoshima M, Kameyama M. Brain content of cobalamin and its binders in elderly subjects. J Nutr Sci Vitaminol 28: 351-357, 1982.
24. Kokkonen J, Similä S. Gastric function and absorption of vitamin B12 in children with celiac disease. Eur J Pediatr 132; (2):71-5, 1979.
25. Lederle FA. Oral cobalamin for pernicious anemia. Medicine’s best kept secret? JAMA. 265: 94-95, 1991.
26. Nilsson-Ehle H, Landahl S, Lindstealt G et al. Low serum cobalamin levels in population study of 70- and 75-year-old subjects. Dig Dis Sci 34: 716-723, 1989.
27. Olszewski AJ, Szostak WB, McCully KS. Plasma glucosamine and galactosamine in ischemic heart disease. Atherosclerosis 75:1-6, 1989.
28. Omaye ST. Nutritional and toxicological aspects of food safety. New York: Plenum Press. p 169-203, 1984.
29. Richardson LR, Brock R. Studies of reproduction in rats using large doses of vitamin Bl2 and highly purified soybean proteins. J Nutr 1956; 58: 135-145.
30. Robertson KR et al. Vitamin B12 Deficiency and Nervous System Disease in HIV Infection, Arch Neurol 50:807-11, 1993.
31. Rule SAJ et al. Serum vitamin B12 and Transcobalamin levels in early HIV Disease. Am J Hematol 47:167-71, 1994.
32. Shemesh Z et al. Vitamin B12 deficiency in patients with chronic tinnitus and noise-induced hearing loss. Am J Otolaryngol 14; (2):94-9, 1993.
33. Shils ME, Young VR. Modem Nutrition in Health and Disease. 7th edn. Lea and Febiger. p 401-404, 1988.
34. Tang AM, Graham NM, Chandra RK, Saah AJ. Low Serum Vitamin B-12 concentrations are associated with Faster Human Immunodeficiency Virus type 1 (HIV-1) disease progression. J Nutr 127:345-51, 1997.
35. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57: 47-53, 1993.
36. Uchizyama M et al. Effects of vitamin B12 on human circadian body temperature rhythm. Neurosci Lett 192: 1-4, 1995.
37. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamin B6, B12, and folate. Am J Epidemiol 143:9:845-59, 1996.
38. Wright J.V. Treatment of childhood asthma with parenteral vitamin B12, gastric reacidification, and attention to food allergy, magnesium and pyridoxine: Three case reports with background and an integrated hypothesis. J Nutr Med 1: 277-82, 1990.

Kilder
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

C-vitamin, ascorbinsyre, forskningsresultater

Admin

Januar 1999

1. Anderson R, Oosthuizen R, Maritz R et al. Effects of increasing weekly doses of ascorbate on certain cellular and humoral immune functions in normal volunteers. Am J Clin Nutr 33: 71-76, 1980.
2. Atkins GL et al. Quantitative aspects of ascorbic acid metabolism in man. J Biol Chem 239:2975-80, 1964.
3. Baetgen D. Results of the treatment of epidemic hepatitis in children with high doses of ascorbic acid in the years 1957 – 1958. Medizinische Monatschrift 15:30-36, 1961 (in German).
4. Baird IM et al. The effects of ascorbic acid and flavonoids on the occurrence of symptoms normally associated with the common cold. Am J Clin Nutr 32: 1686-90, 1979.
5. Baur H, Staub H. Treatment of hepatitis with infusions of ascorbic acid: Comparison with othertherapies. Abstract. JAMA 156; (5): 565, 1954.
6. Bendich A, Langseth L. The health effects of vitamin C supplementation. A review J Am Col Nutr 14: 124-136, 1995.
7. Belfield, WO, Stone, I. Megascorbic prophylaxis and megascorbic therapy: A new orthomolecular modality in veterinary medicine. Journal of the International Academy of Preventive Medicine, 2:10-26, 1975.
8. Bjelke E. Epidemiologic studies of cancer of the stomach, colon and rectum; with special emphasis on diet. Scand J Gastroenterol 9: 1-235S, 1974.
9. Block G. Vitamin C and cancer prevention. The epidemiologic evidence. Am J Clin Nutr 53: 270S-282S, 1991.
10. Blondin J et al. Prevention of eye lens protein damage by dietary vitamin C. Fed Proc 45:478, 1986.
11. Bordia A et al. Effect of vitamin C on platelet adhesiveness and platelet aggregation in coronary artery disease patients. Clin Cardiol 810:552-4, 1985.
12. Bouton SM Jr. Vitamin C and the aging eye. Arch Intern Med 63:930-45, 1939.
13. Brighthope I. AIDS – Remissions using nutrient therapies and megadose intravenous ascorbate. Int Clin Nutr Rev 7; (2):53-75, 1987.
14. Bulpitt CJ. Vitamin C and blodd pressure. J of Hypertension 12; 1071-1075, 1990.
15. Buzina R, Suboticanec K. Vitamin C and physical working capacity. Int Z VitamErnahrungsforsch (Bern) 27: 157-66, 1985; Suboticanec-Buzina K et al. Vitamin C status and physical working capacity in adolescents. Int J Vitam Min Res 54; 1: 55-60, 1984.
16. Calabrese EJ. Does exposure to environmental pollutants increase the need for vitamin C? J Environ Pathol Toxicol Oncol 1985, 5: 81-90, 1985.
17. Calleja HB, Brooks RH. Acute hepatitis treated with high doses of vitamin C. Ohio State Med J 56:821-3, 1960.
18. Cameron, E, Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA, 73:3685-3689, 1976.
19. Cameron, E, Pauling, L. The orthomolecular treatment of cancer: Rereviewuation of prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA, 75:4538-4542, 1978.
20. Cameron, E, Pauling, L. Cancer and Vitamin C. The Linus Pauling Institute for Science and Medicine, Menlo Park, 1979.
21. Campbell, GD Jr., Steinberg, MH and Bower, JD. Ascorbic acid induced hemolysis in G-6-PD deficiency. Ann. Int. Med. 82:810, 1975.
22. Carr AB, Einstein R, Lai LYC, et al. Vitamin C and the common cold: Using identical twins as controls. Med J Aust 2: 8: 411-12, 1981.
23. Cathcart, RF. Clinical trial of vitamin C. Medical Tribune, June 25, 1975.
24. Cathcart, RF. Clinical use of large doses of ascorbic acid. Presented at the annual meeting of the California Orthomolecular Medical Society, San Francisco, February 19, 1976.
25. Cathcart, RF. Vitamin C as a detoxifying agent. Presented at the annual meeting of the Orthomolecular Medical Society, San Francisco, January 21, 1978.
26. Cathcart, RF. Vitamin C – The missing stress hormone. Presented at the annual meeting of the Orthomolecular Medical Society, San Francisco, March 3, 1979.
27. Cathcart, RF. The method of determining proper doses of vitamin C for the treatment of disease by titrating to bowel tolerance. J. Orthomolecular Psychiatry, 10:125-132, 1981.
28. Cathcart RF III. Vitamin C in the treatment of acquired immune deficiency syndrome (AIDS). Med Hypotheses 14; 4:423-33, 1984.
29. Cathcart RF 3rd. Glutathione and HIV infection. Letter. Lancet i:235, 1990; Cathcart RF 3rd. Vitamin C in the treatment of acquired immune deficiency syndrome (AIDS). Med Hypotheses 14; (4):423-33, 1984.
30. Cathcart, RF. The third face of vitamin C. J Orthomol Med 7: 197-200, 1992.
31. Chakrabarty S, Nandi A, Mukhopadhyay C, et al. Protective role of ascorbic acid against lipid peroxidation and myocardial injury. Mol Cell Biochem 111:41-7, 1992.
32. Chamiec T et al. Effects of antioxidant vitamins C and E on signal-averaged electrocardiogram and acute myocardial infarction. Am J Cardiol 77:237-41, 1996.
33. Chandra DB, Varma R, Ahmad S et al. Vitamin C in the human aqueous humor and cataracts. Int J Vit Nutr Res 56: 165 168, 1986.
34. Chandra DB et al. Vitamin C in the human aqueous humor and cataracts. Int J Vitam Nutr Res 56:165-9, 1986.
35. Cheraskin E, Ringsdorf WM Jr, Michael DW et al. Daily vitamin C consumption and reported respiratory findings. Int J Vit Nutr Res 43: 42-55, 1973.
36. Cheraskin E, Ringsdorf WM Jr. Vitamin C and chronologic versus bone age. J Tenn Dent Assoc  57: 177-178, 1974.
37. Cheraskin E, Ringsdorf WM Jr, Medford FH. Daily vitamin C consumption and fatigability. J Am Geriatr Soc 24; (3): 136-7, 1976.
38. Cheraskin E, Ringsdorf WM Jr, Medford FH. The ‘ideal’ daily vitamin C intake. J Med Assoc State Alabama  46: 39-40, 1977.
39. Choi ESK et al. Correlation of plasma ascorbic acid with cardiovascular risk factors. Am J Clin Nutr 51:511, 1990.
40. Cheraskin E, Ringsdorf WM Jr, Sisley EL. The vitamin C connection. New York: Harper & Row. p 1-279, 1983.
41. Cook JD, Watson SS, Simpson KM et al. The effect of high ascorbic acid supplementation on body iron stores. Blood 64: 721-726, 1984.
42. Cousins, N. Anatomy of an Illness as Perceived by the Patient. W.W. Norton & Company, New York, 1979.
43. Cunningham J. Reduced Mononuclear Leukocyte Ascorbic Acid Content in Adults with Insulin-Dependent Diabetes Mellitus Consuming Adequate Dietary Vitamin C. Metabolism 40: 146-49, 1991.
44. Cunningham JJ, Mearkle PL and Brown RG. Vitamin C: An Aldose Reductase Inhibitor that Normalizes Erythrocyte Sorbitol in Insulin-Dependent Diabetes Mellitus. J Am Coll Nutr 4: 344-50, 1994.
45. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol 155:61847-51, 1996.
46. Dallal GE et al. Ascorbic acid, HDL cholesterol, and apolipoprotein A-I in an elderly Chinese population in Boston. J Am Coll Nutr 8;1:69-74, 1989.
47. Davie Sj, Gould BJ and Yudkin JS. Effect of Vitamin C on Glycosylation of Proteins. Diabetes 41: 167-73, 1992.
48. Dawson EB. Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics 62; 1-26, 1990.
49. Devamanoharan P et al. Prevention of selenite cataract by vitamin C. Exp Eye Res 52:563-8, 1991.
50. Dobson HM et al. The effect of ascorbic acid on the seasonal variations in serum cholesterol levels. Scot Med J 293:176-82, 1984.
51. Eaton SB, Shostak M, Konner M. The paleolithic prescription. New York: Harper & Row. p 82,130-131, 1988.
52. Emstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidem 3: 194-202, 1992.
53. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 3:3:194-202, 1992.
54. Erden F, Gulenc S, Torun M et al. Ascorbic acid effect on some lipid fractions in human beings. Acta Vitaminol Enzymol 7: 131-138, 1985.
55. Eriksson J, Kohvakka A. Magnesium and ascorbic acid supplementation in diabetes mellitus. Ann Nutr Metab 394:217-23, 1995.
56. Esk C et al. Correlation of plasma ascorbic acid with cardiovascular risk factors. Clin Res 38:A747, 1990.
57. Fontham ET, Pickle LW, Haenszel W et al. Dietary vitamins A and C and lung cancer risk in Louisiana. Cancer 62: 2267-2273, 1988.
58. Fraga CG. Ascorbic acid protects against endogeneous oxidative DNA damage in human sperm. Proceedings of the National Academy of Sciences 88; 11003-6, 1991.
59. Freudenheim JL, Johnson NE, Smith EL. Relationships between usual nutrient intake and bone-mineral content of women 35-65 years of age. longitudinal and cross-sectional analysis. Am J Clin Nutr 44: 863-876, 1986.
60. Gaby SK, Singh VN. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 103-161, 1991.
61. Gatto LM, Hallen GK, Brown AJ, Samman S. Ascorbic acid induces a favorable lipoprotein profile in women. J Am Coll Nutr 152:154-8, 1996.
62. Gey KF. Scientific evidence for dietary targets in europe bibliotheca nutr deta, vol. 37. Basil: Karger, 1986.
63. Gey KF, Stahelin HB, Eichholzer M. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischemic heart disease and stroke: Basel Prospective Study. Clin Invest 71:3-6, 1993.
64. Ginter E. Cholesterol: Vitamin C controls its transformation to bile acids. Science 179; (74):702-4, 1973.
65. Ghosh J, Das S. reviewuation of vitamin A and C status in normal and malignant conditions and their possible role in cancer prevention. Jpn J Cancer Res 76: 1174-1178, 1985.
66. Ginter E, Cerna O, Budlovsky J et al. Effect of ascorbic acid on plasma cholesterol in humans in a long-term experiment. Int J Vit Nutri Res 47: 123-134, 1977.
67. Ginter E et al. Vitamin C in the control of hypercholesterolemia in man. Int J Vitam Nutr Res Suppl 23:137-52, 1982.
68. Greco AM, Gentile M, DiFilippo O et al. Study of blood vitamin C in lung and bladder cancer patients before and after treatment with ascorbic acid. A preliminary report. Acta Vitaminol Enzymol 4: 155-162, 1982.
69. Greenwood, J. Optimum vitamin C intake as a factor in the preservation of disc integrity. Medical Annals of the District of Columbia, 33:274-276, 1964.
70. Gustafsson U et al. The effect of vitamin C in high doses on plasma and biliary lipid composition in patients with cholesterol gallstones: Prolongation of the nucleation time. Eur J Clin Invest 27:387-91, 1997.
71. Hallberg L, Rossander L. Absorption of iron from Western-type lunch and dinner meals. Am J Clin Nutr 35: 502-509, 1982.
72. Hallfrisch J et al. High plasma vitamin C associated with increased plasma HDL- and HDL 2 -cholesterol. Clin Res 39: A203, 1991.
73. Hallfrisch J, Singh VN, Muller DC, et al. High plasma vitamin C associated with high plasma HDL-and HDL2 cholesterol. Am J Clin Nutr 60:100-5, 1994.
74. Harakeh S, Jariwalla RJ, Pauling L. Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. Proc Natl Acad Sci USA 87; (18):7245-9, 1990.
75. Harakeh S, Jariwalla RJ. Comparative study of the anti-HIV activities of ascorbate and thiol-containing reducing agents in chronically HIV-infected cells. Am J Clin Nutr 54:1231S-5S, 1991.
76. Harakeh S, Jariwalla RJ. Ascorbate Effect on Cytokine Stimulation of HIV Production, Nutrition 11, Suppl. 5: 684-7, 1995.
77. Herbaczynska-Cedro K, Klosiewicz-Wasek B, Cedro K, et al. Supplementation with vitamins C and E suppresses leukocyte oxygen free radical production in patients with myocardial infarction. Eur Heart J 16:1044-9, 1995.
78. Hemilä H. Vitamin C and the common cold. Br J Nutr 67:3-16, 1992.
79. Hemilä H. Vitamin C and plasma cholesterol. Crit Rev Food Sci Nutr 32: 33-57, 1992.
80. Hemilä H. Does vitamin C alleviate symptoms of the common cold? – a review of current evidence. Scand J Infect Dis 26:1-6, 1994.
81. Hemilä H, Herman ZS. Vitamin C and the common cold: A retrospective analysis of Chalmers’ review. J Am Coll Nutr14; (2):116-23, 1995.
82. Hemilä H. Vitamin C supplementation and common cold symptoms: Problems with inaccurate reviews. Nutrition 12; (11-1):804-9, 1996.
83. Hemilä H. Vitamin C and common cold incidence: A review of studies with subjects under heavy physical stress. Int J Sports Med 17; 5: 370-83, 1996.
84. Hemilä H. Vitamin C, the placebo effect, and the common cold: a case study of how preconceptions influence the analysis of results. J Clin Epidemiol 49; 10: 1079-84, 1996.
85. Hemilä H. Vitamin C intake and susceptibility to the common cold. Br J Nutr 77:1-14, 1997.
86. Henson DE. Ascorbic acid: Biologic functions and relation to cancer. J of Nat Cancer Inst 83; 8; 547-550, 1991.
87. Horsey J, Livesley B, Dickerson JW. Ischemic heart disease and aged patients: Effects of ascorbic acid on lipoproteins. J Hum Nutr 35:1:53-8, 1981.
88. Hovi T et al. Topical treatment of recurrent mucocutaneous herpes with ascorbic acid-containing solution. Antivi Res 27; (3):263-70, 1995.
89. Howard PA and Meyers DG, Effect of Vitamin C on Plasma Lipids Pharmacother 29; 1129-36, 1995.
90. Hume R, Weyers E. Changes in leucocyte ascorbic acid during the common cold. Scot Med J 18:3-7, 1973.
91. Jacques PF et al. Ascorbic acid, HDL, and total plasma cholesterol in the elderly. J Am Coll Nutr 6;2:169-74, 1987.
92. Jacques PF. Effects of vitamin C on high-density lipoprotein cholesterol and blood pressure. J Am Coll Nutr 11;2:139-44, 1992.
93. Jacques PF et al., Ascorbic Acid and Plasma Lipids, Epidemiol 5; 19-26, 1994.
94. Jacques PF, Sulsky SI, Perrone GA, Schaefer EJ. Ascorbic acid and plasma lipids. Epidemiology 5:19-24, 1994.
95. Jacques PF, Sulsky SI, Perrone GE, et al. Effect of vitamin C supplementation on lipoprotein cholesterol, apolipoprotein, and triglyceride concentrations. Ann Epidemiol 51:52-9, 1995.
96. Jenkins SA. Vitamin C and gallstone formation: A preliminary report. Experientia 33:1616-17, 1977.
97. Jenkins SA. Biliary lipids, bile acids and gallstone formation in hypovitaminotic C guinea-pigs. Br J Nutr 40:317-22, 1978.
98. Jenkins SA. Vitamin C status, serum cholesterol levels and bile composition in the pregnant guinea-pig. Br J Nutr 43:1:95-100, 1980.
99. Jialal I, Vega Gl, Grundy SM. Physiologic levels of ascorbate inhibit the oxidative modification of low density lipoprotein. Atherosclerosis 82:185-91, 1990.
100. Johnston CS, Luo B. Comparison of the absorption and excretion of three commercially available sources of vitamin C. J Am Dietetic Assoc 94: 779-781, 1994.
101. Kennes B, Dumont 1, Brohee D et al. Effect of vitamin C supplements in cell-mediated immunity in old people. Gerontology 29: 310, 1983.
102. Khaw K-T, et al. Lancet, Vol. 357; 9257: p. 657-663, 2001
103. Khaw K-T, Woodhouse P. Interrelation of vitamin C, infection, hemostatic factors and cardiovascular disease. BMJ 310:1559-63, 1995.
104. Kinsman RA, Hood J. Some behavioral effects of ascorbic acid deficiency. Am J Clin Nutr 24; (4): 455-64, 1971.
105. Klenner, FR. Virus pneumonia and its treatment with vitamin C. J. South. Med. and Surg., 110:60-63, 1948.
106. Klenner, FR. The treatment of poliomyelitis and other viral diseases with vitamin C. J. South. Med. and Surg., 111:210-214, 1949.
107. Klenner FR. Observations on the dose of administration of ascorbic acid when employed beyond the range of a vitamin in human pathology. J Appl Nutr 23; (3&4):61-88, Winter, 1971.
108. Klenner, FR. Significance of high daily intake of ascorbic acid in preventive medicine. J. Int. Acad. Prev. Med., 1:45-49, 1974.
109. Krumdieck C, Butterworth CE Jr. Ascorbate-cholesterollecithin interactions. Factors of potential importance in pathogenesis of atherosclerosis. Am J Clin Nutr 27: 866-876, 1974.
110. Krystal G et al. Stimulation of DNA synthesis by ascorbate in culture of articular chondrocytes. Arthritis Rheum 25: 318-25, 1982.
111. Kune S, Kune GA, Watson LF. Case-control study of dietary etiological factors. The Melbourne Colorectal cancer study. Nutr Cancer 9: 21-42, 1987.
112. Lamden MP, Chrystowski GA. Urinary oxalate excretion by man following ascorbic acid ingestion. Proc Soc Exp Biol Med 85:190-2, 1954.
113. Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 93:6:1107-13, 1996.
114. Levine M, Rumsey S, Wang Y, Park J et al. Vitamin C. In: Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 146-159, 1996.
115. Lewin, S. Vitamin C: Its Molecular Biology and Medical Potential. Academic Press, London, 1976.
116. Li ZY et al. Amelioration of photic injury in rat retina by ascorbic acid: A histopathologic study. Invest Ophthalmol Vis Sci 26:11:1589-98, 1985.
117. Libby, AF and Stone, I. The hypoascorbemia-kwashiorkor approach to drug addiction therapy: A pilot study. J. Orthomolecular Psychiatry, 6:300-308, 1977.
118. Lohmann W. Ascorbic acid and cataract. Ann NY Acad Sci 498: 307-311, 1987.
119. Losonczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr 64:190-6, 1996.
120. Lu SH, Otishima H, Fu HM, Tian Y, Li FM, Blettner M, Wahrendorf J, Bortsch H. Urinary excretion of N-nitrosamino acids and nitrate by inhabitants of high and low-risk areas of esophageal cancer in Northern China. Endogenous formation of nitrosoproline and its inhibition by vitamin C. Cancer Res 46: 1485-1491, 1986.
121. Marshall J, Graham S, Mettlin C et al. Diet in the epidemiology of oral cancer. Nutr Cancer 3: 145-149, 1982.
122. Mena MA, Pardo B, Paino CL, et al. Levodopa toxicity is foetal rat midbrain neurones in culture: Modulation by ascorbic acid. Neuro Rep 4:438-40, 1993.
123. Mezzetti A, Lapenna D, Pierdomenico SD, et al. Vitamins E, C and lipid peroxidation in plasma and arterial tissue of smokers and nonsmokers. Atherosclerosis 112:91-9, 1995.
124. Moran JP, Cohen L, Greene JM et al. Plasma ascorbic acid concentrations relate inversely to blood pressure in human subjects. Am J Clin Nutr 57: 213-217, 1993.
125. Morishige F, Murata A. Vitamin C for prophylaxis of viral hepatitis B in transfused patients. J Int Coll Prev Med 5; (1):54-58, 1978.
126. Muhlmann V et al. Vitamin C therapy of incipient senile cataract. Arch Oftalmol B Aires 14:552-75, 1939.
127. Mullen A, Wilson CWM. The metabolism of ascorbic acid in rheumatoid arthritis. Proc Nutr Sci 35: 8A-9A, 1976.
128. Murata, A. Virucidal activity of vitamin C: Vitamin C for the prevention and treatment of viral diseases. Proceedings of the First Intersectional Congress of Microbiological Societies, Science Council of Japan, 3:432-442, 1975.
129. Ness A, Khaw K, Bingham S, Day NE. Vitamin C status and serum lipids. Eur J Clin Nutr 50; 11:724-9, 1996.
130. Nyyssonen K et al. Vitamin C deficiency and risk of myocardial infarction: Prospective population study of men from Eastern Finland. BMJ 314:634-8, 1997.
131. O’Connor HJ, Habibzedah N, Schorah CJ et al. Effect of increased intake of vitamin C on the mutagenic activity of gastric juice and intrgastric concentrations of ascorbic acid. Carcinogenesis. 6: 1675-1676, 1985.
132. Oldroyd KG, Dawes PT. Clinically significant vitamin C deficiency in rheumatoid arthritis. Br J Rheumatol 24: 362-3, 1985.
133. Organisciak DT et al. The protective effect of ascorbate in retinal light damage of rats. Invest Ophthalmol Vis Sci 26:11:1580-8, 1985.
134. Pauling, L. Vitamin C and the Common Cold. W.H. Freeman and Company, San Francisco, 1970.
135. Pauling, L. Vitamin C, the Common Cold, and the Flu. W.H. Freeman and Company, San Francisco, 1976.
136. Ramirez J, Flowers NC. Leukocyte ascorbic acid and its relationship to coronary artery disease in man. Am J Clin Nutr 33: 2079-2087, 1980.
137. Rath M, Pauling L. Solution to the puzzle of human cardiovascular disease: Its primary cause is ascorbate deficiency leading to the deposition of lipoprotein a and fibrinogen/fibrin in the vascular wall. J Orthomol Med 6:3-4:125-34, 1991.
138. Riemersma RA, Wood DA, MacIntyre CCH, et al. Risk of angina pectoris and plasma concentrations of vitamins A, C and E and carotene. Lancet 337:1-5, 1991.
139. Ringsdorf WM Jr, Cheraskin E. Vitamin C and human wound healing. Oral Surg 53: 231-236, 1982.
140. Riemersma RA, Wood DA, Macintyre CAC et al. Vitamin E. Biochemistry and health implications, vol. 570. New York: Ann NY Acad Sci. p 291-295, 1989.
141. Ringsdorf WM Jr, Cheraskin E. Vitamin C and human wound healing. Oral Surg 53: 231-236, 1982.
142. Rivers JM. Safety of high level vitamin C ingestion. Int J Vitamin Nutr Res 30: 95-102, 1989.
143. Roberts P et al. Vitamin C and inflammation. Med Biol 62:88, 1984.
144. Romney SL, Duttagupta C, Basu J et al. Plasma vitamin C and uterine cervical dysplasia. Am J Obstet Gynecol 151: 976-980, 1985.
145. Sahud MA, Cohen RJ. Effect of aspirin ingestion on ascorbic-acid levels in rheumatoid arthritis. Lancet i: 937-8, 1971.
146. Sahyoun NR et al. Carotenoids, vitamins C and E, and mortality in an elderly population. Am J Epidemiol 144:5:501-11, 1996.
147. Salaman, M. Fighting infection-the cat and the “C”. Let’s Live, 128-130, April 1980.
148. Schorah CJ, Scott DL, Newill A, Morgan DB. Clinical effects of vitamin C in elderly inpatients with low blood-vitamin C levels. Lancet i: 403-5, 1979.
149. Schwartz PL. Ascorbic acid in wound healing: A review. J Am Diet Assoc 56: 497-503, 1970.
150. Schwartz ER. The modulation of osteoarthritic development by vitamins C and E. Int J Vitam Nutr Res Suppl. 26: 141-6, 1984.
151. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 272:1413-20, 1994.
152. Shilotri PG, Bhat KS. Effect of mega doses of vitamin C on bactericidal activity of leukocytes. Am J Clin Nutr 30: 1007-1081, 1977.
153. Siegel, BV. Enhancement of Interferon Response by poly(rI).- poly(rC) in Mouse Cultures by Ascorbic Acid. Nature 254:531-532, 1975.
154. Siegel, BV, Morton, J.I. Vitamin C and the Immune Response. Experientia 33:393-395, 1977.
155. Simon JA, Vitamin C and Cardiovascular Disease: A Review, J Am Coll Nutr 11; 107-125, 1992.
156. Stone, I. Studies of a mammalian enzyme system for producing evolutionary evidence on man. Am. J. Phys. Anthro., 23:83-86, 1965.
157. Stone, I. Hypoascorbemia: The genetic disease causing the human requirement for exogenous ascorbic acid. Perspectives in Biology and Medicine, 10:133-134, 1966.
158. Stone, I. The Healing Factor: Vitamin C Against Disease. Grosset and Dunlap, New York, 1972.
159. Subramanian, N. et al. Detoxification of histamine with ascorbic acid. Biochemical Pharmacology. 27:1671-1673, 1973.
160. Sowers MR, Wallace RB and Lemke JH. Correlates of mid-radius bone density among postmenopausal women. A community study. Am J Clin Nutr 41: 1045-1053, 1985.
161. Stamler J. Nutrition, lipids and coronary heart disease. New York: Raven Press. p 25, 1979.
162. Tannenbaum SR, Wishnok JS, Leaf CD. Inhibition of nitrosamine formation by ascorbic acid. Am J Clin Nutr 53: 247S-250, 1991.
163. Terezhalmy GT, Bottomley WK, Pelleu GB. The use of water-soluble bioflavonoid-ascorbic acid complex in the treatment of recurrent herpes labialis. Oral Surg Oral Med Oral Pathol 45; (1):56-62, 1978.
164. Tomoda H, Yoshitake M, Morimoto K, Aoki N, et al. Possible prevention of postangioplasty restenosis by ascorbic acid. Am J Cardiology 78;11:1284-6, 1996.
165. Toohey L et al. (Low) Plasma ascorbic acid concentrations are related to cardiovascular risk factors in African-Americans. J Nutr 126:121-8, 1996.
166. Turley S et al. Role of ascorbic acid in the regulation of cholesterol metabolism and the pathogenesis of atherosclerosis. Atherosclerosis 24:1-18, 1976.
167. Vallance BD, Hume R, Weyers E. Reassessment of changes in leucocyte and serum ascorbic acid after acute myocardial infarction. Br Heart J 40;1:64-8, 1978.
168. Varma SD, Richards RD. Light-induced damage to ocular lens cation pump: Prevention by vitamin C. Proc Natl Acad Sci U S A 76: 3504-6, 1979.
169. Varma SD et al. Photoperoxidation of lens lipids: Prevention by vitamin E. Photochem Photobiol 36:6:623-36, 1982.
170. Varma SD. Ascorbic acid and the eye with special reference to the lens, in JJ Burns, JM Rivers, LJ Machlin, Eds. Third Conference on Vitamin C. New York, New York Academy of Sciences 498: 280-306, 1987.
171. Vinson JA et al. In Vitro and in Vivo Reduction of Erythrocyte Sorbitol by Ascorbic Acid. Diabetes 38: 1036-41, 1989.
172. Vitale S et al. Plasma vitamin C, E and beta carotene levels and risk of cataract. Invest Ophthalmol Vis Sci 32:723, 1991.
173. Wandzilak TR, D’andre SD, Davis PA, Williams HE. Effect of high dose vitamin C on urinary oxalate levels. J Urol 151:834-837, 1994.
174. Wartamowicz M, Panczenko-Kresowka B, Ziemlaski S et al. The effect of alpha-tocopherol and ascorbic acid on the serum lipid peroxide level in elderly people. Ann Nutr Metabol 28: 186-191, 1984.
175. Wassertheil-Smoller S, Romney SC, Wylie-Rosett J et al. Dietary vitamin C and uterine cervical dysplasia. Am J Epidemiol 114: 714-724, 1981.
176. Weisburger J. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 53: S226-237, 1991.
177. Weisburger JH. Vitamin C and disease prevention. J Am Col Nutr 14: 109-111, 1995.
178. Will EJ, Bijvoet OL. Primary oxalosis: Clinical and biochemical response to high-dose pyridoxine therapy. Metabolism 28; 5:542-548, 1979.
179. Williams, RJ. The Prevention of Alcoholism Through Nutrition. Bantam Books, New York, 1981.
180. Williams, RJ. Biochemical Individuality. John Wiley, New York, 1956. University of Texas Press, Austin, Texas, 1973.
181. Yapa S. Detection of subclinical ascorbate deficiency in early Parkinson’s disease. Public Health 106:393-5, 1992.
182. Yoshioka M, Matsushita T, Chuman Y. Inverse association of serum ascorbic acid level and blood pressure or rate of hypertension in male adults aged 30-39 years. Int J Vit Nutr Res 54: 343-347, 1984.
183. Ziemlanski S, Wartanowicz M, Potrzebnicka K et al. Ascorbic acid and tocopherol levels in the organs and serum of guinea pigs with experimentally induced atherosclerosis. Acta Physiol Pol 40: 552-557, 1989.
184. Zureick M. Treatment of shingles and Herpes with Vitamin C intravenously. J des Praticiens 64:586, 1950.


Kilder
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.